MIR-205-5p-mediated downregulation of ERBB/HER receptors in breast cancer stem cells results in targeted therapy resistance

Cell Death and Disease

Volumn 6, Issue 7, 2015, Pages

  De Cola, A ^a   Volpe, S ^b   Budani, M C ^a   Ferracin, M ^c   Lattanzio, R ^a   Turdo, A ^b   D'Agostino, D ^a   Capone, E ^a   Stassi, G ^b   Todaro, M ^b   Di Ilio, C ^a   Sala, G ^a,d   Piantelli, M ^a   Negrini, M ^c   Veronese, A ^a   De Laurenzi, V ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d MediaPharma Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MICRORNA; MICRORNA 205 5P; PROTEIN P63; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; LAPATINIB; MIRN205 MICRORNA, HUMAN; QUINAZOLINE DERIVATIVE; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER STEM CELL; CANCER TISSUE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY RESISTANCE; UPREGULATION; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEINS;

EID: 84954309948     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.192     Document Type: Article

References (41)

1. Liu S, Clouthier SG, Wicha MS. Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 2012; 17: 15-21.
2. Spielmann M, Roché H, Delozier T, Canon J-L, Romieu G, Bourgeois H et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27: 6129-6134.
3. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 88-96.
4. Arteaga CL, Sliwkowski MX, Osborne CK, Perez E a, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32.
5. Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 2011; 11: 793-800.
6. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
7. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005; 122: 553-563.
8. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999; 216: 671-680.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
10. Calin GA, Konopleva M. Small gene, big number, many effects. Blood 2012; 120: 240-241.
11. Farmer DT, Shariat N, Park CY, Liu HJ, Mavropoulos A, McManus MT. Partially penetrant postnatal lethality of an epithelial specific MicroRNA in a mouse knockout. PLoS One 2013; 8: e76634.
12. Greene SB, Gunaratne PH, Hammond SM, Rosen JM. A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci 2010; 123: 606-618.
13. Wu H, Zhu S, Mo Y-Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19: 439-448.
14. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
15. Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med 2011; 9: 30.
16. Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 2012; 7: e46990.
17. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-2295.
18. Tran MN, Choi W, Wszolek MF, Navai N, Lee I-LC, Nitti G et al. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem 2013; 288: 3275-3288.
19. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci USA 2012; 109: 15312-15317.
20. Allocati N, Di Ilio C, De Laurenzi V. P63/P73 in the control of cell cycle and cell death. Exp Cell Res 2012; 318: 1285-1290.
21. Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta 2011; 1816: 57-66.
22. D'Aguanno S, Barcaroli D, Rossi C, Zucchelli M, Ciavardelli D, Cortese C et al. P63 isoforms regulate metabolism of cancer stem cells. J Proteome Res 2014; 13: 2120-2136.
23. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumabtreated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
24. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin cancer Res 2008; 14: 360-365.
25. Wiemer EAC. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007; 43: 1529-1544.
26. Avril-Sassen S, Goldstein LD, Stingl J, Blenkiron C, Le Quesne J, Spiteri I et al. Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics 2009; 10: 548.
27. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath C V, Schwartz G et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-11620.
28. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 2007; 21: 3238-3243.
29. Greene S, Herschkowitz J, Rosen J. The ups and downs of miR-205: identifying theroles of miR-205 in mammary gland development and breast cancer. RNA Biol 2011; 7: 300-304.
30. Danilov AV, Neupane D, Nagaraja AS, Feofanova EV, Humphries LA, DiRenzo J et al. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS One 2011; 6: e26815.
31. Yu J, Ryan DG, Getsios S, Oliveira-Fernandes M, Fatima A, Lavker RM. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci USA 2008; 105: 19300-19305.
32. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69: 2195-2200.
33. Wang D, Zhang Z, O'Loughlin E, Wang L, Fan X, Lai EC et al. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI3K pathway. Nat Cell Biol 2014; 15: 1153-1163.
34. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
35. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G et al. miR-203 represses "stemness" by repressing DeltaNp63. Cell Death Differ 2008; 15: 1187-1195.
36. Candi E, Terrinoni A, Rufini A, Chikh A, Lena AM, Suzuki Y et al. p63 is upstream of IKK alpha in epidermal development. J Cell Sci 2006; 119: 4617-4622.
37. Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A et al. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J Exp Med 2004; 200: 1257-1266.
38. Rocco JW, Leong CO, Kuperwasser N, De Young MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
39. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
40. De Cola A, Bongiorno-Borbone L, Bianchi E, Barcaroli D, Carletti E, Knight RA et al. FLASH is essential during early embryogenesis and cooperates with p73 to regulate histone gene transcription. Oncogene 2012; 31: 573-582.
41. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.